DE 120

Drug Profile

DE 120

Alternative Names: DE-120

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santen Incorporated
  • Developer Santen Inc
  • Class Eye disorder therapies
  • Mechanism of Action Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-II for Wet age-related macular degeneration in USA (Intravitreous) (Santen Pipeline, August 2017)
  • 31 Oct 2016 Santen completes a phase II trial in Wet age-related macular degeneration in USA (Intravitreous) (NCT02401945)
  • 21 Apr 2016 Santen completes a phase II trial in Wet age-related macular degeneration in USA (NCT02022501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top